Results 1 to 10 of about 51,322 (300)

Bullous Pemphigoid and Other Pemphigoid Dermatoses [PDF]

Medicina, 2021
The pemphigoid family of dermatoses is characterized by autoimmune subepidermal blistering. The classic paradigm for pemphigoid, and the most common member, is bullous pemphigoid.
Valeryia Pratasava, Vikram N. Sahni, Aishwarya Suresh, Simo Huang, Abhirup Are, Sylvia Hsu, Kiran Motaparthi   +6 more
doaj   +4 more sources

Comorbidity in bullous pemphigoid: up-date and clinical implications

Frontiers in Immunology, 2023
Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous ...
Johanna Huttelmaier, Sandrine Benoit, Matthias Goebeler   +2 more
doaj   +2 more sources

Dyshidrosiform Bullous Pemphigoid [PDF]

Medicina, 2021
Dyshidrosiform bullous pemphigoid is a variant of bullous pemphigoid. At least 84 patients with dyshidrosiform bullous pemphigoid have been described. Dyshidrosiform bullous pemphigoid usually presents with pruritic blisters in elderly individuals; the ...
Philip R. Cohen
doaj   +3 more sources

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

BMC Endocrine Disorders, 2021
Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid.
Vaia Lambadiari, Aikaterini Kountouri, Foteini Kousathana, Emmanouil Korakas, Georgios Kokkalis, Sofia Theotokoglou, Lina Palaiodimou, Pelagia Katsimbri, Ignatios Ikonomidis, Konstantinos Theodoropoulos, Evangelia Papadavid   +10 more
doaj   +2 more sources

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

Acta Dermato-Venereologica, 2021
Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors.
Aikaterini Tsiogka, Johann W. Bauer, Aikaterini Patsatsi   +2 more
doaj   +2 more sources

A Systematic Review of Drug-Induced Pemphigoid

Acta Dermato-Venereologica, 2020
Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus followed by urticarial plaques and finally bullae on the skin and mucosa.
Matthew J. Verheyden, Asli Bilgic, Dédée F. Murrell   +2 more
doaj   +2 more sources

New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report [PDF]

SAGE Open Medical Case Reports
Bullous pemphigoid is recognized as the most prevalent autoimmune blistering skin disease. This report presents a case of a 54-year-old male in Canada who developed new-onset bullous pemphigoid 4 weeks after receiving his fifth COVID-19 vaccine booster ...
Eman Badawod
doaj   +2 more sources

Dupilumab as a treatment for bullous pemphigoid in a liver transplant recipient: A case report [PDF]

SAGE Open Medical Case Reports
Bullous pemphigoid is a common subepidermal autoimmune bullous disease that affects the skin and mucous membranes. It is more prevalent in the elderly, often resulting in significant morbidity and mortality.
Sarah S. Rashid, P. Régine Mydlarski, Fatemeh Jafarian   +2 more
doaj   +2 more sources

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Journal of the European Academy of Dermatology and Venereology, 2022
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions.
L. Borradori, N. van Beek, C. Feliciani, B. Tedbirt, E. Antiga, R. Bergman, B. Böckle, M. Caproni, F. Caux, N. S. Chandran, G. Cianchini, M. Daneshpazhooh, D. De, D. Didona, G. Di Zenzo, M. Dmochowski, K. Drenovska, J. Ehrchen, M. Goebeler, R. Groves, C. Günther, B. Horváth, M. Hertl, S. Hofmann, D. Ioannides, B. Itzlinger-Monshi, J. Jedlickova, C. Kowalewski, K. Kridin, Y. L. Lim, B. Marinović, A. Marzano, J. Mascaro, J. Meijer, D. Murrell, K. Patsatsi, C. Pincelli, C. Prost, K. Rappersberger, M. Sárdy, J. Setterfield, M. Shahid, E. Sprecher, K. Tasanen, S. Uzun, S. Vassileva, K. Vestergaard, A. Vorobyev, I. Vujic, G. Wang, K. Wozniak, S. Yaylı, G. Zambruno, D. Zillikens, E. Schmidt, P. Joly   +55 more
semanticscholar   +1 more source

Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid

Acta Dermato-Venereologica, 2023
Current research on the malignancy rate and spectrum of malignancies in patients with bullous pemphigoid is contradictory. The aims of this study were to determine the prevalence and spectrum of malignancy in patients with bullous pemphigoid and to ...
Sharon Baum, Shani Steinberg, Ido Tzanani , Aviv Barzilai , Anna Lyakhovitsky   +4 more
doaj   +1 more source